StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for BIAF yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.84 | $1.69 | -8.42% | 0.1M |
| 05-19 | $1.67 | $1.70 | +1.80% | 0.1M |
| 05-20 | $1.70 | $1.66 | -2.35% | 0.2M |
| 05-21 | $1.61 | $1.62 | +0.62% | 0.2M |
| 05-22 | $1.61 | $1.56 | -3.11% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.35M | $6.16M | $4.57M | $3.12M |
Operating Income | $-3.62M | $-10.57M | $-7.44M | $-5.14M |
Net Income | $-3.63M | $-14.91M | $-11.77M | $-6.72M |
EPS (Diluted) | $-0.81 | $-8.66 | $-7.55 | $-0.20 |
Total Assets | $7.95M | $10.96M | $11.55M | $4.75M |
Total Liabilities | $4.28M | $3.68M | $2.64M | $6.89M |
Cash & Equivalents | $3.10M | $6.45M | $7.67M | $802.84K |
Free Cash Flow OCF − CapEx | $-3.23M | $-9.39M | $-6.83M | $-4.35M |
Shares Outstanding | 4.50M | 4.50M | 3.47M | 28.46M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.